Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia ; The University of Melbourne, Parkville, Victoria, Australia.
PLoS One. 2013 Aug 21;8(8):e70536. doi: 10.1371/journal.pone.0070536. eCollection 2013.
Suppressor of Cytokine Signaling (SOCS)5 is thought to act as a tumour suppressor through negative regulation of JAK/STAT and epidermal growth factor (EGF) signaling. However, the mechanism/s by which SOCS5 acts on these two distinct pathways is unclear. We show for the first time that SOCS5 can interact directly with JAK via a unique, conserved region in its N-terminus, which we have termed the JAK interaction region (JIR). Co-expression of SOCS5 was able to specifically reduce JAK1 and JAK2 (but not JAK3 or TYK2) autophosphorylation and this function required both the conserved JIR and additional sequences within the long SOCS5 N-terminal region. We further demonstrate that SOCS5 can directly inhibit JAK1 kinase activity, although its mechanism of action appears distinct from that of SOCS1 and SOCS3. In addition, we identify phosphoTyr317 in Shc-1 as a high-affinity substrate for the SOCS5-SH2 domain and suggest that SOCS5 may negatively regulate EGF and growth factor-driven Shc-1 signaling by binding to this site. These findings suggest that different domains in SOCS5 contribute to two distinct mechanisms for regulation of cytokine and growth factor signaling.
细胞因子信号转导抑制因子(SOCS)5 被认为通过负向调控 JAK/STAT 和表皮生长因子(EGF)信号通路而发挥肿瘤抑制作用。然而,SOCS5 作用于这两条不同通路的机制尚不清楚。我们首次表明,SOCS5 可以通过其 N 端的独特保守区域直接与 JAK 相互作用,我们将其称为 JAK 相互作用区(JIR)。SOCS5 的共表达能够特异性地降低 JAK1 和 JAK2(但不是 JAK3 或 TYK2)的自身磷酸化,而这一功能需要保守的 JIR 和 SOCS5 N 端长区域内的其他序列。我们进一步证明 SOCS5 可以直接抑制 JAK1 激酶活性,尽管其作用机制与 SOCS1 和 SOCS3 不同。此外,我们鉴定出 Shc-1 上的磷酸化 Tyr317 是 SOCS5-SH2 结构域的高亲和力底物,并表明 SOCS5 可能通过与该位点结合来负向调控 EGF 和生长因子驱动的 Shc-1 信号通路。这些发现表明,SOCS5 中的不同结构域有助于调控细胞因子和生长因子信号的两种不同机制。